Literature DB >> 9108443

p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth.

M Bonfanti1, S Taverna, M Salmona, M D'Incalci, M Broggini.   

Abstract

We tested the ability of synthetic peptides derived from p21(WAF1), fused to the internalization peptide sequence derived from Antennapedia, to inhibit the growth of cancer cells in two human ovarian cancer cell lines expressing wild-type p53 or not. Two fused peptides corresponding to p21(WAF1) regions 17-33 and 63-77 inhibited cell growth in both cell lines while the same peptides without the internalization sequence were inactive. The fused peptides prevented growth at concentrations which inhibited cyclin-dependent kinase 2 and cdc2 activity, thus demonstrating that the peptides act by mimicking the action of p21(WAF1) on kinases. This study illustrates the potential pharmacological use of small peptides fused with the Antennapedia internalization sequence in proliferative disorders. The approach may be extended to other diseases in which cell penetration of a peptide may be of therapeutic benefit. More stable drug-like molecules with better pharmacological properties could be designed based on the results obtained with peptides.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108443

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

Review 1.  Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors.

Authors:  Guillaume Drin; Christophe Rousselle; Jean-Michel Scherrmann; Anthony R Rees; Jamal Temsamani
Journal:  AAPS PharmSci       Date:  2002

2.  Targeting the RB pathway for cancer therapy: peptide mimetic foundations and promise.

Authors:  Razvan T Radulescu; Robin Fahraeus
Journal:  Am J Transl Res       Date:  2010-03-30       Impact factor: 4.060

3.  Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.

Authors:  Bin Yang; Ling Gao; Lin Li; Zhixian Lu; Xuejun Fan; Charvi A Patel; Roger J Pomerantz; Garrett C DuBois; Hui Zhang
Journal:  J Biol Chem       Date:  2002-12-11       Impact factor: 5.157

4.  Antitumor activity of cell-permeable p18(INK4c) with enhanced membrane and tissue penetration.

Authors:  Junghee Lim; Jungeun Kim; Tam Duong; Guewha Lee; Junghee Kim; Jina Yoon; Jaetaek Kim; Hyuncheol Kim; H Earl Ruley; Wael El-Rifai; Daewoong Jo
Journal:  Mol Ther       Date:  2012-05-22       Impact factor: 11.454

5.  Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells.

Authors:  Anna-Marija Helt; Jens Oliver Funk; Denise A Galloway
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

6.  TAT-mediated intracellular delivery of NPM-derived peptide induces apoptosis in leukemic cells and suppresses leukemogenesis in mice.

Authors:  Yun Zhou; Wei Du; Tara Koretsky; Grover C Bagby; Qishen Pang
Journal:  Blood       Date:  2008-06-23       Impact factor: 22.113

7.  Inhibition of ovarian cancer cell proliferation by a cell cycle inhibitory peptide fused to a thermally responsive polypeptide carrier.

Authors:  Iqbal Massodi; Shama Moktan; Aruna Rawat; Gene L Bidwell; Drazen Raucher
Journal:  Int J Cancer       Date:  2010-01-15       Impact factor: 7.396

Review 8.  CNS delivery via adsorptive transcytosis.

Authors:  Françoise Hervé; Nicolae Ghinea; Jean-Michel Scherrmann
Journal:  AAPS J       Date:  2008-08-26       Impact factor: 4.009

9.  Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine.

Authors:  E Erba; L Bassano; G Di Liberti; I Muradore; G Chiorino; P Ubezio; S Vignati; A Codegoni; M A Desiderio; G Faircloth; J Jimeno; M D'Incalci
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

10.  Generation of a selectively cytotoxic fusion protein against p53 mutated cancers.

Authors:  Christina A Kousparou; Efthymia Yiacoumi; Mahendra P Deonarain; Agamemnon A Epenetos
Journal:  BMC Cancer       Date:  2012-08-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.